Proton Pump Inhibitors in the COVID-19 Pandemic
The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in p...
Saved in:
| Main Authors: | T. E. Kugler, I. S. Malovichko, V. B. Gnilitskaya, A. L. Khristulenko, N. F. Yarovaya |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
SINAPS LLC
2022-08-01
|
| Series: | Архивъ внутренней медицины |
| Subjects: | |
| Online Access: | https://www.medarhive.ru/jour/article/view/1477 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proton pump inhibitors - possible side effects of long-term therapy: a review
by: Jan Kowalewski, et al.
Published: (2024-12-01) -
Proton Pump Inhibitors and Gastric Cancer
by: Seungkyung Kang, et al.
Published: (2021-09-01) -
Concomitant use of metformin and proton pump inhibitors increases vitamin B12 deficiency risk in type 2 diabetes
by: Choungwon Jung, et al.
Published: (2025-06-01) -
By correcting hyperhomocysteinemia and background in dyslipidemia of prolonged use of proton pump inhibitors
by: A. V. Zharkova
Published: (2013-02-01) -
Gastroesophageal reflux disease, resistant to proton pump inhibitors
by: V. O. Kaybysheva, et al.
Published: (2011-06-01)